Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BridgeBio Pharma, Inc.

Get SEC filing alerts via email and in your feed for BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering transformative medicines for genetic diseases. Its core products include Attruby/Beyonttra, an oral therapy for transthyretin amyloid cardiomyopathy, and late-stage clinical candidates targeting achondroplasia, autosomal dominant hypocalcemia, and limb girdle muscular dystrophy. BridgeBio leverages genetic insights and innovative drug platforms to address high unmet medical needs, serving patients through regulatory approvals and strategic partnerships.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BridgeBio Pharma, Inc.

1
1
BridgeBio Pharma, Inc. BridgeBio Pharma Reports $194.5M Revenue in Q1 2026, Driven by Attruby Sales

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
BridgeBio Pharma, Inc. BridgeBio Pharma Reports $502.1M Revenue in 2025, Highlights Attruby's Success

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
BridgeBio Pharma, Inc. BridgeBio Pharma Reports $120.7M Revenue in Q3 2025, Driven by Attruby Launch

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BridgeBio Pharma, Inc. BridgeBio Pharma Reports $110.6M Revenue and $183.8M Net Loss for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BridgeBio Pharma, Inc. BridgeBio Pharma Reports Significant Revenue Decline and Increased Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BridgeBio Pharma, Inc. BridgeBio Pharma Reports Q3 2024 Financial Results, Significant Restructuring, and Milestone Payment Opportunity

Via official filing (AI summary) | over 1 year ago | 0 comments